Adrian Jubb, M.B. Ch.B., Ph.D.

Chief Medical Officer

Adrian Jubb, M.B. Ch.B., Ph.D., F.R.C.Path., joined Immune-Onc as our Chief Medical Officer in July 2018. Adrian is a physician-scientist with 17 years of experience across research and clinical development in oncology, infectious disease and neuroscience. Most recently, Adrian served as Vice President and Head of Early Development at Achaogen where he played a leading role in the development and FDA approval of ZEMDRI for the treatment of serious multi-drug resistant infections. Prior to Achaogen, Adrian was a Medical Director in Oncology at Genentech and supported numerous oncology clinical development programs over the course of his tenure, including AVASTIN®, MetMAb, COTELLIC® and Apo2L.

Adrian holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree, with honors, from the Faculty of Medicine and Health at the University of Leeds, United Kingdom. His scientific training was conducted in the research laboratories of Genentech, leading to the award of a Ph.D. through the University of Leeds. Adrian is also a Fellow of the Royal College of Pathologists (F.R.C.Path.), having completed joint clinical and academic postgraduate training at the Oxford Deanery and the University of Oxford, United Kingdom. Following his training, Dr. Jubb was appointed to a faculty position in the Nuffield Department of Clinical Laboratory Sciences, University of Oxford, where he led several projects in the fields of angiogenesis and oncology as a principal investigator. Adrian has authored over 55 scientific publications, including numerous first and senior author papers in top-tier journals (e.g., Journal of Clinical Oncology, Lancet Oncology, Nature Reviews Cancer), and is a named inventor on 4 issued patents.